Has Farxiga lost patent exclusivity in 2026?
Farxiga (dapagliflozin) is still covered by intellectual-property protection that can include both patents and market-exclusivity rights, but whether it “lost exclusivity in 2026” depends on the specific country and the specific type of exclusivity being considered (patent term vs. regulatory exclusivity vs. any granted extensions). With the information provided here, there isn’t enough detail to confirm that Farxiga’s exclusivity ended specifically in 2026.
What counts as “exclusivity” for Farxiga—patent or regulatory protection?
In practice, “exclusivity” claims can refer to:
- Patent expiry for one or more formulations/uses/chemistry claims, which may differ across jurisdictions.
- Regulatory exclusivities (where applicable), which can extend market protection beyond the first patent expiry.
- Country-specific manufacturing or data-protection rules that affect when generics or biosimilars (not relevant here since Farxiga is a small molecule) can enter.
How to check whether 2026 is the end date in your country
To verify the 2026 timeline, you typically need:
- The jurisdiction (U.S., EU/UK, Canada, etc.).
- The relevant product (Farxiga/dapagliflozin) and the market authorization details.
- The specific patent list and expiry dates tied to that jurisdiction’s drug approval and whether any patent term extensions apply.
What happens if exclusivity ends—do generics start immediately?
Even after the “last” relevant exclusivity ends, entry timelines can still depend on:
- Whether any remaining patents are still in force and whether generic manufacturers are blocked by litigation or “skinny label” strategies.
- The approval pathway (e.g., when the generic application can be accepted vs. when it can launch).
- Local regulatory requirements for labeling and switching.
If you tell me your country, I can narrow it down
If you share the country/region you mean (for example, U.S. or EU/UK) and whether you mean “patent expiry” or “regulatory exclusivity,” I can help pinpoint the likely expiry/exclusivity window for Farxiga in that jurisdiction.
Sources
No sources were provided with your question, so I can’t verify an exclusivity/patent end date for 2026 from the supplied information.